The mRNA synthesis and manufacturing market's potential lies in the increasing demand for mRNA therapeutics and vaccines, driven by COVID-19 successes. Opportunities include mRNA custom synthesis and ...

Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 6.4% in the afternoon session after a major long-term study from France indicated that its COVID-19 vaccine was safe and effective.

More than a year after its promised deadline to investors, drugmaker puts alarming results in federal government's "virtual ...

KAIST researchers have developed a method that attaches DNA fragments to mRNA to slow the onset of protein production, ...

RNA, widely known from the COVID-19 vaccine, is not actually a "therapeutic agent," but a technology that delivers the ...

Vaccinated adults had a 74 percent lower risk of dying from COVID-19—and a 25 percent lower risk of dying, period.

Researchers at the Icahn School of Medicine at Mount Sinai and collaborators have reported early success with a novel ...

Even supporters of mRNA vaccination against COVID-19 might be surprised at just how much higher death rates are among the ...

Developers of mRNA therapeutics face an increasingly complex landscape: rising expectations for potency and durability, ...

The memo, written by FDA chief medical and scientific officer Vinay Prasad, reviewed 96 pediatric deaths and concluded that “no fewer than 10” were likely linked to COVID-19 shots. The deaths were ...

Syantra, Inc., a biotechnology company revolutionizing cancer detection, is announcing Scottsdale, Arizona based Vincere Cancer Center has launched recruitment for clinical testing to evaluate the ...

The U.S. government is turning its back on a medical breakthrough that has saved millions of lives, halting $500 million in ...